表紙
市場調查報告書

急性缺血性腦中風 (AIS):全球治療藥的預測、市場分析 2027年

Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027

出版商 GlobalData 商品編碼 737759
出版日期 內容資訊 英文 184 Pages
訂單完成後即時交付
價格
急性缺血性腦中風 (AIS):全球治療藥的預測、市場分析 2027年 Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027
出版日期: 2018年07月27日內容資訊: 英文 184 Pages
簡介

急性缺血性腦中風 (AIS)的主要8個市場 (美國、法國、德國、義大利、西班牙、英國、日本、中國) 的治療藥的銷售額,2017年約為72億美金。其中美國是最大的市場,構成主要8個市場銷售額的47% (34億美元)。

本報告提供全球急性缺血性腦中風 (AIS)的治療藥市場相關調查,市場成長的主要的促進因素,新治療藥的價格、醫療費償付的展望,治療藥的可能性和未滿足需求的應對,專利趨勢,最新的開發平台藥物的銷售後的機會等相關分析。

第1章 目錄

第2章 急性缺血性腦中風:摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理學
  • 分期的分類

第5章 流行病學

  • 疾病的背景
  • 風險因素、合併症
  • 全球、過去趨勢
  • 預測手法
  • AIS的流行病學預測
  • 討論

第6章 疾病管理

  • 診斷、治療概要
  • 治療指南
  • 美國
  • EU5個國家
  • 日本
  • 中國

第7章 競爭評估

  • 概要

第8章 未滿足需求、機會的評估

  • 概要
  • 更安全有效的血栓溶解
  • 改善臨床結果的有效治療
  • 2次性中風的預防治療的長期性遵守
  • 迅速診斷、急性治療的獲取

第9章 開發平台評估

  • 概要
  • 臨床開發的有潛力醫藥品

第10章 現在、未來的企業

  • 概要
  • 企業策略趨勢
  • Roche:組合評估
  • Boehringer Ingelheim:組合評估
  • Bristol-Myers Squibb:組合評估
  • Janssen:組合評估
  • 第一三共
  • AstraZeneca:組合評估
  • ZZ Biotech:組合評估
  • NoNO Inc.:組合評估
  • Biogen:組合評估
  • Athersys:組合評估
  • SanBio:組合評估

第11章 市場展望

  • 全球市場
  • 美國
  • EU5個國家
  • 日本
  • 中國

第12章 附錄

目錄
Product Code: GDHC171PIDR

Sales of drugs in the AIS market (including TIA) were approximately $7.2B in 2017 in the 8MMthe US, five major European countries (5EU: France, Germany, Italy, Spain, and the UK), Japan, and China. The US was the largest market, with sales of $3.4B, representing 47% of all sales from the 8MM. The highest-selling drug in the market was Roche's Activase (alteplase), which generated sales of $1.2B in the 8MM in 2017.

Stroke is caused by the interruption of the blood supply to the brain, usually because a cerebral blood vessel ruptures and bleeds (hemorrhagic stroke) or is blocked by a clot (ischemic stroke), which obstructs blood flow and oxygen and nutrients from reaching the brain, causing death of the local brain tissue (infarction). Stroke is a leading cause of disability and death worldwide and a common cause of dementia, associated with significant social and economic impact.

The Acute Ischemic Stroke (AIS) market is about to enter an exciting phase over the next decade with novel therapies entering the market that are designed to improve stroke outcome. Global sales in the Acute Ischemic Stroke (AIS) market are expected to growat a compound annual growth rate (CAGR) of 3.9% till 2027. The main drivers of growth will be the launch of three novel neuroprotective agents (NA-1, BIIB093, and 3K3A-APC) and one stem cell therapy (MultiStem) aimed at improving clinical outcome post-stroke when given in the acute phase of stroke, along with Activase or endovascular treatment (EVT) or both. One stem cell therapy, SB623, is designed to reduce disability in patients with chronic stroke, potentially given years after the initial event.

"Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027", report helps in some very specific question of the Acute Ischemic Stroke (AIS) Market. They are -

  • What are the key drivers of significant growth of the Acute Ischemic Stroke (AIS) market?
  • What are the pricing and reimbursement prospects for the upcoming novel therapies?
  • What is the market potentials of drugs developed for the treatment of Acute Ischemic Stroke (AIS), and would they fulfill the greatest unmet needs in this space?
  • How will key patent expiries of novel anticoagulants (NOACs) impact sales of current and launching therapies in Acute Ischemic Stroke (AIS)?
  • Will there be opportunities remaining after the launch of late pipeline drugs in Acute Ischemic Stroke (AIS)?

Scope:

  • Overview of AIS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized AIS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AIS therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global AIS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global AIS therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AIS therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Acute Ischemic Stroke: Executive Summary

  • 2.1. AIS Market Forecast to Reach $10.6B by 2027
  • 2.2. The AIS Late-Stage Pipeline Focus on Improving Stroke Outcome
  • 2.3. Current Treatments Leave High Level of Unmet Need in the AIS Market
  • 2.4. Opportunities Will Remain for New Entrants
  • 2.5. Late-Stage Pipeline Drugs Entering the AIS Market Will Be a Key Driver of Growth
  • 2.6. What Do Physicians Think?

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
    • 4.1.1. Etiology
    • 4.1.2. Pathophysiology
  • 4.2. Classification or Staging Systems

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global and Historical Trends
  • 5.4. Forecast Methodology
    • 5.4.1. Sources
    • 5.4.2. Forecast Assumptions and Methods
  • 5.5. Epidemiological Forecast for AIS (2017-2027)
    • 5.5.1. First-Ever Diagnosed Incident Cases of AIS
    • 5.5.1. Age-Specific First-Ever Diagnosed Incident Cases of AIS
    • 5.5.2. Sex-Specific First-Ever Diagnosed Incident Cases of AIS
    • 5.5.3. Recurrent Diagnosed Incident Cases of AIS
    • 5.5.4. First-Ever Diagnosed Incident Cases of AIS by TOAST Subtype
    • 5.5.5. Diagnosed Prevalent Cases of AIS
    • 5.5.6. Age-Specific Diagnosed Prevalent Cases of AIS
    • 5.5.7. Sex-Specific Diagnosed Prevalent Cases of AIS
    • 5.5.8. AIS Mortality
  • 5.6. Discussion
    • 5.6.1. Epidemiological Forecast Insight
    • 5.6.2. Limitations of Analysis
    • 5.6.3. Strengths of Analysis

6. Disease Management

  • 6.1. Diagnosis and Treatment Overview
    • 6.1.1. AIS
    • 6.1.2. TIA
  • 6.2. Treatment Guidelines
  • 6.3. US
  • 6.4. 5EU
  • 6.5. Japan
  • 6.6. China

7. Competitive Assessment

  • 7.1. Overview

8. Unmet Needs and Opportunity Assessment

  • 8.1. Overview
  • 8.2. Safer and More Effective Thrombolysis
  • 8.3. Effective Therapies to Improve Clinical Outcome
  • 8.4. Long-Term Compliance with Secondary Stroke Prevention Therapies
  • 8.5. Access to Rapid Diagnosis and Acute Treatment

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Promising Drugs in Clinical Development
    • 9.2.1. Neuroprotective Agents
    • 9.2.2. Stem Cell Therapies

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Roche Portfolio Assessment
  • 10.4. Boehringer Ingelheim Portfolio Assessment
  • 10.5. Bristol-Myers Squibb Portfolio Assessment
  • 10.6. Janssen Portfolio Assessment
  • 10.7. Daiichi Sankyo Portfolio Assessment
  • 10.8. AstraZeneca Portfolio Assessment
  • 10.9. ZZ Biotech Portfolio Assessment
  • 10.10. NoNO Inc. Portfolio Assessment
  • 10.11. Biogen Portfolio Assessment
  • 10.12. Athersys Portfolio Assessment
  • 10.13. SanBio Portfolio Assessment

11. Market Outlook

  • 11.1. Global Markets
    • 11.1.1. Forecast
    • 11.1.2. Drivers and Barriers - Global Issues
  • 11.2. US
    • 11.2.1. Forecast
    • 11.2.2. Key Events
    • 11.2.3. Drivers and Barriers
  • 11.3. 5EU
    • 11.3.1. Forecast
    • 11.3.2. Key Events
    • 11.3.3. Drivers and Barriers
  • 11.4. Japan
    • 11.4.1. Forecast
    • 11.4.2. Key Events
    • 11.4.3. Drivers and Barriers
  • 11.5. China
    • 11.5.1. Forecast
    • 11.5.2. Key Events
    • 11.5.3. Drivers and Barriers

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Methodology
    • 12.3.1. Forecasting Methodology
    • 12.3.2. Diagnosed Patients
    • 12.3.3. Percent Drug-Treated Patients
    • 12.3.4. Drugs Included in Each Therapeutic Class
    • 12.3.5. Launch and Patent Expiry Dates
    • 12.3.6. General Pricing Assumptions
    • 12.3.7. Individual Drug Assumptions
    • 12.3.8. Generic Erosion
    • 12.3.9. Pricing of Pipeline Agents
  • 12.4. Primary Research - KOLs Interviewed for This Report
    • 12.4.1. KOLs
    • 12.4.2. Primary Research - Prescriber Survey
  • 12.5. About the Authors
    • 12.5.1. Analyst
    • 12.5.2. Therapy Area Director
    • 12.5.3. Epidemiologist
    • 12.5.4. Managing Epidemiologist
    • 12.5.5. Global Director of Therapy Analysis and Epidemiology
    • 12.5.6. Global Head and EVP of Healthcare Operations and Strategy
  • 12.6. About GlobalData
  • 12.7. Contact Us
  • 12.8. Disclaimer

List of Tables

  • Table 1: AIS: Key Metrics in the 8MM
  • Table 2: TOAST Classification of Subtypes of AIS
  • Table 3: Risk Factors and Comorbidities for AIS
  • Table 4: Evaluation of Patients with Suspected Acute Ischemic Stroke or Transient Ischemic Attack
  • Table 5: Criteria for Thrombolysis Using Activase in Patients with AIS
  • Table 6: ABCD2 Score Used for Risk of Stroke Assessment
  • Table 7: Treatment Guidelines for AIS and TIA
  • Table 8: Country Profile - US
  • Table 9: Country Profile - 5EU
  • Table 10: Country Profile - Japan
  • Table 11: Country Profile - China
  • Table 12: Leading Treatments for AIS and TIA, 2018
  • Table 13: Roche's AIS/TIA Portfolio Assessment, 2018
  • Table 14: Boehringer Ingelheim's AIS Portfolio Assessment, 2018
  • Table 15: Bristol-Myers Squibb's AIS Portfolio Assessment, 2018
  • Table 16: Janssen's AIS Portfolio Assessment, 2018
  • Table 17: Daiichi Sankyo's AIS Portfolio Assessment, 2018
  • Table 18: AstraZeneca's AIS Portfolio Assessment, 2018
  • Table 19: ZZ Biotech's AIS Portfolio Assessment, 2018
  • Table 20: NoNO Inc.'s AIS Portfolio Assessment, 2018
  • Table 21: Biogen's AIS Portfolio Assessment, 2018
  • Table 22: Athersys' AIS Portfolio Assessment, 2018
  • Table 23: SanBio's AIS Portfolio Assessment, 2018
  • Table 24: AIS Market - Global Drivers and Barriers, 2017-2027
  • Table 25: Key Events Impacting Sales for AIS and TIA in the US, 2017-2027
  • Table 26: AIS Market - Drivers and Barriers in the US, 2017-2027
  • Table 27: Key Events Impacting Sales for AIS in the 5EU, 2017-2027
  • Table 28: AIS Market - Drivers and Barriers in the 5EU, 2017-2027
  • Table 29: Key Events Impacting Sales for AIS in Japan, 2017-2027
  • Table 30: AIS Market - Global Drivers and Barriers in Japan, 2017-2027
  • Table 31: Key Events Impacting Sales for AIS in China, 2017-2027
  • Table 32: AIS Market - Global Drivers and Barriers in China, 2017-2027
  • Table 33: Key Historical and Projected Launch Dates for AIS
  • Table 34: Key Historical and Projected Patent Expiry Dates for AIS
  • Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for AIS in 2017 and 2027
  • Figure 2: Analysis of the Company Portfolio Gap in AIS During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of AIS During the Forecast Period
  • Figure 4: Main Types and Processes of Acute Ischemic Stroke (AIS) and Its Management
  • Figure 5: Stroke-Induced Neuronal Cell Death and Therapeutic Targets of Pipeline Candidates
  • Figure 6: 8MM, Age-Standardized First-Ever Diagnosed Incidence of AIS, Men, Ages ≥18 Years, 2007-2027
  • Figure 7: 8MM, Age-Standardized First-Ever Diagnosed Incidence of AIS, Women, Ages ≥18 Years, 2007-2027
  • Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of AIS, Men, Ages ≥18 Years, 2007-2027
  • Figure 9: 8MM, Age-Standardized Diagnosed Prevalence of AIS, Women, Ages ≥18 Years, 2007-2027
  • Figure 10: Sources Used and Not Used for First-Ever Diagnosed Incident Cases of AIS
  • Figure 11: Sources Used and Not Used for Recurrent Diagnosed Incident Cases of AIS
  • Figure 12: Sources Used and Not Used for First-Ever Diagnosed Incident Cases of AIS by TOAST Subtype
  • Figure 13: Sources Used and Not Used for Diagnosed Prevalent Cases of AIS
  • Figure 14: Sources Used and Not Used for AIS Mortality
  • Figure 15: 8MM, First-Ever Diagnosed Incident Cases of AIS, Men and Women, Ages ≥18 Years, 2017
  • Figure 16: 8MM, Age-Specific First-Ever Diagnosed Incident Cases of AIS, Men and Women, 2017
  • Figure 17: 8MM, Sex-Specific First-Ever Diagnosed Incident Cases of AIS, Ages ≥18 Years, 2017
  • Figure 18: 8MM, Recurrent Diagnosed Incident Cases of AIS, Ages ≥18 Years, Men and Women, 2017
  • Figure 19: 8MM, First-Ever Diagnosed Incident Cases of AIS by TOAST Subtype, Ages ≥18 Years, Men and Women, 2017
  • Figure 20: 8MM, Diagnosed Prevalent Cases of AIS, Men and Women, Ages ≥18 Years, 2017
  • Figure 21: 8MM, Age-Specific Diagnosed Prevalent Cases of AIS, Men and Women, 2017
  • Figure 22: 8MM, Sex-Specific Diagnosed Prevalent Cases of AIS, Ages ≥18 Years, 2017
  • Figure 23: 8MM, AIS Mortality, Ages ≥18 Years, Men and Women, 2017-2027
  • Figure 24: Acute Ischemic Stroke Management
  • Figure 25: Transient Ischemic Attack Management
  • Figure 26: Unmet Needs and Opportunities in AIS and TIA
  • Figure 27: Overview of the Development Pipeline in AIS and TIA
  • Figure 28: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for AIS or TIA or Both in the 8MM During the Forecast Period
  • Figure 29: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of AIS During the Forecast Period
  • Figure 30: Analysis of the Company Portfolio Gap in AIS and TIA During the Forecast Period
  • Figure 31: Global (8MM) Sales Forecast by Country for AIS and TIA Combined in 2017 and 2027
  • Figure 32: Sales Forecast by Class for AIS and TIA Combined in the US in 2017 and 2027
  • Figure 33: Sales Forecast by Class for AIS and TIA Combined in the 5EU in 2017 and 2027
  • Figure 34: Sales Forecast by Class for AIS and TIA Combined in Japan in 2017 and 2027
  • Figure 35: Sales Forecast by Class for AIS and TIA Combined in China in 2017 and 2027